Gynecologic Oncology

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

Amid advances in gene-based cancer diagnostics, questions about the best use of molecular and cellular assays in practice are growing along with the new options for clinicians.

Useful Online Resources and Clinical Trials for Ovarian Cancer

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

The Internet has been employed in a variety of interesting ways to foster clinical or research agendas.

In the United States, gynecologic cancers affect nearly 80,000 women annually and are the cause of death in more than 25,000 women.

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.

In May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.

A false-positive result on a mammogram may trigger anxiety and decrease quality of life, and the effects may remain apparent a year later, new data suggest.

For women who have survived childhood cancer, breastfeeding may help counter some of the long-term complications that occur as a result of their prior cancer treatments, researchers say.

Everolimus (Afinitor) added to tamoxifen delayed tumor progression in patients with hormone receptor (HR)-positive, HER2-negative, advanced metastatic breast cancer

Two trials explored the role of lapatinib (Tykerb) as neoadjuvant therapy in early-stage HER2-positive breast cancer and concluded that its effectiveness is statistically no better than standard trastuzumab (Herceptin) therapy

Investigators for Study 136 say that an additional 4 months of follow-up data have confirmed earlier findings that denosumab (Xgeva) is superior to zoledronic acid (Zometa) at preventing skeletal-related events

Adjuvant treatment of stage II and III breast cancer with zoledronic acid (Zometa) failed to improve disease-free survival (DFS) in the large

Women with untreated advanced breast cancer had a trend toward greater clinical benefit with fulvestrant (Faslodex) versus anastrozole (Arimidex) as first-line hormonal therapy

Aromatase inhibitor use appears to increase the risk of cardiotoxicity in women with early-stage breast cancer, albeit slightly.

Exemestane (Aromasin) was no better than anastrozole (Arimidex) at reducing cancer recurrence in postmenopausal women with hormone receptor-positive primary breast cancer

The risk of colorectal cancer declined by 33% among postmenopausal women taking oral bisphosphonates for osteoporosis

GlaxoSmithKline%u2019s experimental cervical cancer vaccine Cervarix has proven 100% effective in preventing precancerous lesions due to cancer-causing human papillomavirus (HPV) strains 16 and 18 for up to five and a half years.

The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 21 leading cancer centers worldwide, develops and publishes clinical practice guidelines to promote the importance of continuous quality improvement. The primary goal of all its initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

Studies have also shown that diet and exercise help prevent breast cancer, yet obesity rates in women continue to rise. New information suggests women with early stage breast cancer can prolong their lives by following a prudent diet.

Conventional cancer chemotherapy has enjoyed mixed success because it fails to differentiate patients by the unique molecular characteristics of their disease.

Breast cancer in general is not openly discussed in Malaysia, but this may be changing.

The purpose of this Priority Report is to raise awareness of metastatic breast cancer.